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24
th
 November 2018 
Prof. Rajiv Jalan 
Editor-in-Chief 
Journal of Hepatology 
 
Dear Prof. Jalan, 
 
On behalf of all co-authors, we would like to submit a reply letter entitled “Reply to 
Correspondence Concerning Models For Prediction Of Early Recurrence of HCC After Surgical 
Resection Of Hepatocellular Carcinoma” to respond four Letters to the Editors commenting our 
recent paper concerning early recurrence after resection of Hepatocellular Carcinoma (HCC) (J 
Hepatol. 2018 Dec;69(6):1284-1293. doi: 10.1016/j.jhep.2018.08.027). Those four letters include  
1. “Time to Recurrence, But Not Recurrence-free Survival, Should Be the Endpoint of 
Predicting Early Recurrence after HCC Resection” (JHEPAT-D-18-01944) by Wen-Tao 
Yan et al. 
2. “Predicting early hepatocellular carcinoma recurrence after resection: a comment for moving 
forward” (JHEPAT-D-18-01803R1) by Xiao-Ying Zhang et al. 
3. “Toward the universal scoring system in treatment for patients with hepatocellular 
carcinoma” (JHEPAT-D-18-01939) by Jiro Kusakabe et al. 
4. “Factors Predicting Early Recurrence After Surgical Resection of Hepatocellular Carcinoma” 
(JHEPAT-D-18-01989) by Yao-Ming Zhang et al. 
  
Thank you for your attention. 
 
Yours sincerely, 
 
Philip J Johnson, MD, FRCP 
Professor in Translational Oncology 
Institute of Translational Medicine 
Department of Clinical Cancer Medicine 
University of Liverpool 
Cover Letter
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We are grateful to your correspondents [1-4] for their interest in, and comment on, our recent 
paper concerning early recurrence after resection of Hepatocellular Carcinoma (HCC).[5] 
 
As Royston et al., have pointed out ‘Surprisingly, there is no widely agreed approach to 
building a multivariable prognostic model from a set of candidate predictors’.[6] In building 
our prognostic models we have two guiding principles. Firstly, those variables involved 
should be readily available in all centers treating patients with HCC. Secondly, again as 
emphasized by Royston et al., the models should be ‘transportable’ ‘i.e. broadly, if not 
universally, applicable’. To achieve these criteria, we need large cohorts from multiple 
centers, worldwide. With these two principles in mind we had to be pragmatic both in the 
variables used to develop the models and the datasets available to us for analysis. Thus, the 
price to pay, in most cases, for the large numbers is that we have to accept those cohorts that 
have already been collected. We are not in a position to specify exactly what variables are in 
the cohort, and we acknowledge that this not ideal. We are pursuing prospective studies to 
validate our models and collect other relevant variables not included in the original study. 
 
The variables entering the final models 
Like Zhang X.Y. et al., and Zhang Y.M. et al.,[3, 4] we found it surprising that macrovascular 
invasion (MaVI), a well-described risk factor for early recurrence after resection, was not in 
our final models. Had we considered MaVI in isolation (i.e. just in a univariate analysis), 
MaVI was a risk factor (HR 3.306, P<0.001). However, it was not an independent predictor in 
the multivariable analyses, a finding in agreement with other authors.[7, 8] When all 
identified risk factors are considered in a multivariable model, the presence or absence of 
MaVI does not add to the predictive utility of our model. Indeed, if we rebuild the model but 
exclude any one of the significant parameters (male gender, multiple tumors, tumor size or 
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AFP, except ALBI) then MaVI does enter the model.  
 
Zhang Y.M. et al. questioned the high figure for microvascular invasion (MiVI) in the US 
series.[4] In our study we assumed that all patients with MaVI also had MiVI. We have 
confirmed the figures in the US series. The rate of MiVI in resected specimen was 44.6% 
(similar to that in Italy, 49.5%) and 28.6% for MaVI, giving the figure reported in Table 1 of 
73.1%.  
 
With regards to the inclusion of gender into our models,[4] we can only report what the 
analysis showed and recognize that multivariable models only relate to statistical associations 
and offer no insight into the underlying mechanism of the factors identified. In fact, Shim et 
al. also demonstrated that male gender was an independent risk factor associated with early 
recurrence in their cohort of 1085 patients.[8] Although it is unclear why male patients are 
prone to early recurrence, they may have more aggressive HCCs than female patients.[9] 
   
Kusakabe et al. expressed concern that certain variables were excluded.[1] We have examined 
the effect of excluding the variables ALT, ALP, INR and positive margin on the performance 
of the ERASL-pre and ERASL-post models. Although the excluded variables modestly 
improved the fit of the model (LR test, P=0.0121 and P=0.0102), there was no further 
improvement in the survival prediction, as measured by Harrell’s C index (P=0.064 and 
P=0.060). There was also no added enhancement in survival prediction when both models 
were rebuilt with the excluded variables added back in (P=0.107 and P=0.161).  
 
All the variables in our study refer to the pre-operative assessment apart from MiVI which 
was only available after histological examination of the resected tumor and is only involved 
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in the post-operative model. We acknowledge that more accurate information about tumor 
size, number and MaVI might be forthcoming after visual inspection of the liver at the time of 
operation, but doubt that any changes will have a major impact on the model performance.  
  
Issues surrounding the ALBI score 
The ALBI score is an evidence-based and extensively validated refinement/simplification of 
the Child-Pugh score (CPS).[10, 11] Its performance is at least as good or, more often, better 
than the CPS.[12] Yan et al.,[2] expressed surprise that ALBI, a measure of liver function, 
entered our early recurrence models since liver function is usually considered to be a factor 
influencing long term survival after HCC resection and indeed we have previously confirmed 
this in relation to ALBI.[13] Hsu et al., also reported, in a study of over 1900 patients 
undergoing resection, that ALBI was an independent factor associated with early 
recurrence.[14] Why this should be so must remain speculative, but one possibility is that a 
fraction of ‘early recurrences’ may actually be ‘de novo’ tumor. Such cases might be expected 
to occur more frequently in patients with poor liver function in more advanced underlying 
chronic liver disease. 
 
We acknowledge that, in principle, it is preferable to consider continuous variables in their 
continuous form rather than after categorization. In the event however, replacing the ALBI 
grade with the ALBI score did not improve the survival prediction of the model: ERASL-
pre,(P=0.716 and P=0.422 respectively) and ERASL-post,(P=0.644 and P=0.913 respectively).  
 
Again, a case for applying albumin and bilirubin as separate parameters in developing our 
models can be made. However, such an approach risks losing the conceptual basis of the 
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score as a measure of liver function and the same issue would arise in applying any composite 
score (e.g. CPS or tumor stage) in a multivariable model.  
 
Issues concerning early deaths 
A small percentage of patients (<10%) died before their recurrence status was known.  In our 
study, that aimed to predict recurrence within the first two years of resection, we censored all 
deaths within this period.  We believe this was the correct procedure but acknowledge, as Yan 
et al.,[2] point out, that this approach would be more appropriately labelled as ‘time to 
recurrence’ rather than ‘recurrence free survival’. 
 
Might the models suggest which sub-group of HCC patients would benefit from 
transplantation rather than resection? 
As noted by Kusakabe et al.,[1] it is likely that at least those in the high risk ERASL group, 
would do better with transplantation although it will be difficult to design a study to formally 
predict the optimal potentially curative treatment. We have already shown that the ‘cure 
fraction’ after transplantation for HCC is 74.1% compared to only 24.1% in the cases 
undergoing resection.[15] In the near future we hope to be able to add a figure for ‘likelihood 
of cure’ at the individual patient level, to the ERASL model. 
 
Conclusion 
It is inventible that different researchers using different datasets and different statistical 
methodologies will arrive at different prognostic models. Like Kusakabe et al.,[1] we are 
aiming to develop an overarching model for HCC. To this end we have collected a database 
of around 150,000 cases with detailed clinical data and are starting to apply machine learning 
and artificial intelligence in addition to conventional statistical methodology. The only way to 
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arrive at a comprehensive and consistent model will be through large collaborative projects 
involving high quality datasets, preferably prospectively-collected. We hope the present study, 
and the lessons learnt therefrom, will be a significant step in the right direction. 
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